KUWAIT DRUGS

 

SEARCH

 

SUGGESTIONS

 

ADD PRODUCTS

 

HOME

0-9    A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

 

 

PREVIOUS

  

NEXT

 
 

IMURAN 50 MG TABLETS

 

 
 

 

GENERIC NAMES

MANUFACTURERS 

MEDICAL GROUP

MEDICAL ARTICLES

 

DRUGS IN :

 

 

FDA DRUGS

UNITED STATES

CANADA

UNITED KINGDOM

AUSTRALIA

GERMANY

FRANCE

MIDDLE EAST

KUWAIT

LEBANON

EGYPT

SYRIA

BAHRAIN

IRAN

JORDAN

SAUDI ARABIA

UNITED ARAB EMIRATES

 

 

 
 

SIZE:

50 MG

 

GENERIC NAME:

AZATHIOPRINE

 

MANUFACTURER:

GLAXO WELLCOME

 

UNIT:

 

ADMINISTRATION ROUTE:

 

FDA PREGNANCY GROUP:

D

 

INDICATIONS:

Arthritis, rheumatoid

Rejection, renal transplant, prophylaxis

 

SIDE EFFECTS:

Leukopenia or infection

megaloblastic anemia

Hepatitis or biliary stasis

thrombocytopenia

Gastrointestinal hypersensitivity reaction

hepatic veno-occlusive disease

hypersensitivity

pancreatitis, hypersensitivity

pneumonitis

sores in mouth and on lips

Loss of appetite

nausea or vomiting

Skin rash

Bone marrow depression, delayed

 

ABSOLUTE CONTRAINDICATIONS :

 

RELATIVE CONTRAINDICATIONS :

>> Chickenpox, existing

>> Herpes zoster

>> Gout

>> Hepatic function impairment

>> Infection

Pancreatitis

>> Renal function impairment

>> Sensitivity to azathioprine

>> Xanthine oxidase deficiency, severe

 

ADULT DOSE:

Transplant rejection, organ (prophylaxis)-Initial: Oral, 3 to 5 mg per kg of body weight or 120 mg per square meter of body surface area a day, one to three days before or at the time of surgery, the dosage being adjusted to maintain the homograft without causing toxicity. Maintenance: Oral, 1 to 3 mg per kg of body weight or 45 mg per square meter of body surface area a day. Rheumatoid arthritis or [Bowel disease, inflammatory] or [Cirrhosis, biliary] or [Dermatomyositis, systemic] or [Glomerulonephritis] or [Hepatitis, chronic active] or [Lupus erythematosus, systemic] or [Myopathy, inflammatory] or [Myasthenia gravis] or [Nephrotic syndrome] or [Pemphigoid] or [Pemphigus] -Initial: Oral, 1 mg per kg of body weight a day, the dosage being increased in increments of 500 mcg (0.5 mg) per kg of body weight a day after six to eight weeks, then every four weeks as necessary up to a maximum dose of 2.5 mg per kg of body weight a day. Maintenance: Oral, the dosage being reduced to the minimum effective dose in decrements of 500 mcg (0.5 mg) per kg of body weight a day every four to eight weeks.

 

MAXIMUM ADULT DOSE:

 

PEDIATRIC DOSE:

Transplant rejection, organ (prophylaxis)-Initial: Oral, 3 to 5 mg per kg of body weight or 120 mg per square meter of body surface area a day, one to three days before or at the time of surgery, the dosage being adjusted to maintain the homograft without causing toxicity. Maintenance: Oral, 1 to 3 mg per kg of body weight or 45 mg per square meter of body surface area a day. Rheumatoid arthritis or [Bowel disease, inflammatory] or [Cirrhosis, biliary] or [Dermatomyositis, systemic] or [Glomerulonephritis] or [Hepatitis, chronic active] or [Lupus erythematosus, systemic] or [Myopathy, inflammatory] or [Myasthenia gravis] or [Nephrotic syndrome] or [Pemphigoid] or [Pemphigus] -Initial: Oral, 1 mg per kg of body weight a day, the dosage being increased in increments of 500 mcg (0.5 mg) per kg of body weight a day after six to eight weeks, then every four weeks as necessary up to a maximum dose of 2.5 mg per kg of body weight a day. Maintenance: Oral, the dosage being reduced to the minimum effective dose in decrements of 500 mcg (0.5 mg) per kg of body weight a day every four to eight weeks. 

 

MAXIMUM PEDIATRIC DOSE:

 

ELDERLY DOSE:

 

 

PREVIOUS

  

NEXT